
PDRN, made without animal-derived sources
Advancing PDRN across five fields of human biology
Dermatology
Preclinical
We are investigating PDRN in burns, wounds that are slow to close, ageing skin and hair regrowth.
Orthopaedics
Research
We are investigating PDRN in knee osteoarthritis, tendon injury and delayed bone healing.
Cardiology
Research
We are investigating PDRN in impaired circulation of the lower limbs and diabetic foot ulcers.
Gastroenterology
Research
We are investigating PDRN in inflammatory bowel disease and periodontal disease.
Neurology
Research
We are investigating PDRN in carpal tunnel syndrome and persistent neuropathic pain following injury.
Each programme is shown at the stage it has reached today. No Synthena PDRN programme has entered clinical trials, and no Synthena PDRN medicine has been approved for any indication.
A focus on building blocks the body already uses
Every cell relies on nucleotides to build and repair its DNA. Research suggests that as PDRN is broken down, its components can enter nucleotide salvage pathways. We are developing PDRN without animal-derived starting material, with tight control over the length of the DNA fragments we produce.


A narrower, defined range
Our target fragments are 20–80 base pairs, approximately 13–53 kilodaltons. PDRN described in the scientific literature commonly spans a much broader range.
- Chae et al., 2025
- Squadrito et al., 2017
- Galeano et al., 2021

From defined material to medicine
Through control over how PDRN is made, we aim to bring a defined, consistent material from the bench toward medicines that can change patients' lives.

A number never stands alone.